41. AARP - Health, Travel Deals, Baby Boomers, Election News, Over 50, Online Games, Both forms of graftvs.-host disease bring with them an increased risk of infections, either because of the process itself or its treatment with cortisone-like drugs and http://healthtools.aarp.org/galecontent/graft-vs-host-disease

AARP tips UUXData.serveAd( 728 , 90 ); Join/ Renew Join Renew ... Sign In New Here? Register Membership Community Help Hello, Messages Logout Membership Community ... AARP UUXData.serveAd( 180 , 35 ); Home Health Health Care Reform Longevity ... Member Benefits Most Popular Articles Viewed Body Mass Index Calculator You Can Beat Diabetes ... Raking Leaves Recommended Commented HEALTH ENCYCLOPEDIA Find health information about medical conditions, symptoms, and medical procedures. A B C D ... Z Graft vs Host Disease basic INFO image GALLERY Description Graft-vs.-host disease is a response by the immune system that occurs when cells from a blood or bone marrow donor attack those of the recipient. The only transplanted tissues that contain enough immune cells to cause graft-vs.-host disease are the blood and the bone marrow. Blood transfusions are used every day in hospitals for many reasons. Bone marrow transplants are used to replace blood-forming cells and immune cells in cancer patients whose own bone marrow has been destroyed by radiation therapy or chemotherapy Blood transfusion graft-vs.-host disease affects mostly the blood. Blood cells perform three functions: carrying oxygen, fighting infections, and clotting. All of these functions are decreased in a transfusion graft-vs.-host reaction, leading to

42. Cancer Drug Shows Promise Against Graft Vs. Host Disease A new University of Michigan study in mice suggests that a drug recently approved to fight cancer tumors is also able to reduce the effects of graftversus-host disease, a http://www.physorg.com/news134925182.html

Science and technology news Home Nanotechnology Physics ... Neuroscience Cancer drug shows promise against graft vs. host disease July 10, 2008 Pavan Reddy, M.D., a University of Michigan researcher, led a study in mice showing that drugs known as HDAC inhibitors show promise in preventing graft vs. host disease. Credit: U-M Photo Services: Martin Vloet A new University of Michigan study in mice suggests that a drug recently approved to fight cancer tumors is also able to reduce the effects of graft-versus-host disease, a common and sometimes fatal complication for people who have had bone marrow transplants. Plans are under way at U-M for an initial trial of the drug in people as a new way to prevent graft-versus-host disease. Researchers expect to begin a trial within a year. The U-M scientists tested the effects of the drug SAHA, as well as another member of a group of drugs known as HDAC inhibitors, on key immune system cells called dendritic cells. In mice, both drugs were able to significantly diminish the destructive inflammatory effects that these cells cause in graft-versus-host disease. Graft-versus-host disease occurs when immune cells in the transplanted bone marrow mount a misguided attack on body tissues. If HDAC inhibitors turn out to be safe and effective in people, they might offer a treatment option preferable to the immunosuppressant drugs used now to treat the disease. These leave people vulnerable to infection and have other significant side effects.

43. Graft-vs-Host Disease: Nutrition Therapy In A Challenging Condition — Nutr Cli Susan Roberts, MS, RD, LD, CNSD; Jennifer Thompson, RD, LD, CNSD; Baylor University Medical Center, Dallas, Texas; Correspondence Susan Roberts, MS, RD, LD, CNSD, Baylor http://ncp.sagepub.com/content/20/4/440.abstract

var callbackToken='4274E2DA7C18D96'; Sign In to gain access to subscriptions and/or My Tools. Sign In My Tools Contact Us HELP Search all journals Advanced Search Search History Browse Journals Skip to main page content ... Email Alerts Search this journal Advanced Journal Search » Graft- vs -Host Disease: Nutrition Therapy in a Challenging Condition Susan Roberts , MS, RD, LD, CNSD Jennifer Thompson , RD, LD, CNSD Baylor University Medical Center, Dallas, Texas Correspondence: Susan Roberts, MS, RD, LD, CNSD, Baylor University Medical Center Nutrition Services, 3500 Gaston Avenue, Dallas, TX 75246. Electronic mail may be sent to Abstract Graft- vs American Society for Parenteral and Enteral Nutrition CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this? « Previous Next Article » Table of Contents This Article doi: Nutr Clin Pract August 2005 vol. 20

44. Ocular Graft Vs. Host Disease: Diagnosis And Management By Ladan Espandar, MD, Majid Moshirfar, MD, FACS, and Stella K. Kim, MD Edited by Ingrid U. Scott, MD, MPH, and Sharon Fekrat, MD http://www.aao.org/publications/eyenet/200810/pearls.cfm

Print Version Login October 2008 Feature The Clinical Challenges of Managing a Pain in the Eye Clinical Insights Ocular Graft vs. Host Disease: Diagnosis and Management When the Diagnosis is Elder Abuse Gentle Care for the Anophthalmic or Microphthalmic Child Global Vision, Part Five: The Eyes of Eastern Europe Clinical Challenges Morning Rounds: What's Your Diagnosis? Blink Mystery Image News Journal Highlights News in Review Academy Notebook Destination Atlanta Practice Management PQRI 2009 — Three New Measures and an Increase Bonus Efficiency, Liability and the Role of the Technician Opinions Entitlement: Do You Feel You Deserve It? Industry Money: Protecting Our Integrity? Letters Ophthalmic Pearls: Comprehensive Diagnosis and Management of Ocular Graft vs. Host Disease By Ladan Espandar, MD, Majid Moshirfar, MD, FACS, and Stella K. Kim, MD Edited by Ingrid U. Scott, MD, MPH, and Sharon Fekrat, MD Hematopoietic stem cell transplantation is used to treat a variety of malignancies and hematologic, immunogenic and metabolic disorders. Allogeneic stem cell transplantation can cause graft vs. host disease (GVHD), which is associated with high mortality and morbidity. In the past, any manifestation of GVHD within 100 days after transplantation was referred to as “acute GVHD,” and after 100 days it was called “chronic GVHD.” The NIH Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD has changed the classification and staging of GVHD. New classification.

45. Graft-vs.-host Disease - Definition, Description, Causes And Symptoms, Treatment , Causes and symptoms, Treatment, Prognosis, Prevention Disease, Host, Graft, Blood, Cells, Marrow, Bone, and Immune......Graftvs.-host Disease - Definition, http://health.stateuniversity.com/pages/669/Graft-vs-host-Disease.html

46. Graft-versus-Host Disease (GVHD) Klaas Scleroderma Graftvs-Host Disease (GVHD) So I would like to know if, and when, I will be able to walk again (Spanish/Espa ol) Klaas Sclerodermia da GVHD Essiste un modo http://www.sclero.org/medical/symptoms/associated/similar/graft-vs-host-disease/

Sclero.org is the most important thing in the world to know about scleroderma and PAH, in 23 languages: Arabic Chinese Deutsche/German ... Worldwide Support Groups Get a FREE warm hug at Search sclero.org: ANY match ALL words EXACT Help Get our free Sclero e-Newsletter! Home Medical News Sclero Forums ... Donate Sclero Awareness Scleroderma Awareness Bracelets , just $2.50 each. In Loving Memory Of Patricia Allee Judy Tarro Donate in Memory PAH? Earn $50! Earn $50! WWMR, a division of IntrinsiQ, is searching for patients diagnosed with pulmonary hypertension (PAH or PH) or their caregivers to serve on their marketing research panel. Read more. Thanks to Recent Donors Gary Allee Lisa Bulman's Scoring for Scleroderma Tournament Linda Bush Michelle Fraser Lynn Goodwin Massachusetts Bay Transportation McGraw-Hill Companies Nancy Paul Winnifred Schillberg Joan Schrimsher Melissa Shea United Way of Massachusetts Bay United Way of Snohomish County Donate or Shop Now Volunteer for Sclero! We have openings for volunteer support group leaders, fund raisers and grant writers. Apply today!

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 3     41-46 of 46    Back | 1  | 2  | 3